Management of high-risk pulmonary embolism in pregnancy

Thromb Res. 2021 Aug:204:57-65. doi: 10.1016/j.thromres.2021.05.019. Epub 2021 Jun 7.

Abstract

Pregnancy-associated high-risk pulmonary embolism (PE) is among the most frequent causes of maternal mortality in the Western world, by causing hemodynamic instability and circulatory failure through a large thrombotic pulmonary obstruction. The very challenging management of these dramatic situations comprises the need to quickly select a therapy of pulmonary reperfusion or hemodynamic replacement, while taking into account both maternal and fetal risks. In this review, we discuss the role of risk stratification in pregnancy-associated PE and the available evidence to support the use of thrombolysis, catheter-directed thrombectomy/thrombolysis, surgical embolectomy and extracorporeal membrane oxygenation. Despite the lack of comparative studies and solid evidence, most reported cases of high-risk pregnancy-associated PE have been treated with thrombolysis, with high maternal and fetal survivals, and thrombolysis is suggested by guidelines in life-threatening PE. For women in the peripartum and early post-partum period, non-fibrinolytic treatments may be preferred as a first-line treatment, if available, because of the particularly high bleeding risk. In all cases, pregnancy-associated high-risk PE requires a multidisciplinary approach involving PE response teams and obstetricians.

Keywords: Extracorporeal membrane oxygenation; Postpartum period; Pregnancy; Pulmonary embolism; Thrombolytic therapy; Venous thromboembolism.

Publication types

  • Review

MeSH terms

  • Embolectomy
  • Extracorporeal Membrane Oxygenation*
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Pregnancy
  • Pulmonary Embolism* / drug therapy
  • Thrombectomy
  • Thrombolytic Therapy
  • Treatment Outcome

Substances

  • Fibrinolytic Agents